Recursion Pharmaceuticals (NASDAQ:RXRX) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Recursion Pharmaceuticals (NASDAQ:RXRX) from a strong sell rating to a hold rating in a research report released on Saturday.

Several other research firms have also commented on RXRX. Bank of America decreased their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, January 22nd. Needham & Company LLC restated a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday. Morgan Stanley set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th. Finally, UBS Group set a $11.00 price target on Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $9.40.

Recursion Pharmaceuticals Stock Down 2.7%

Recursion Pharmaceuticals stock opened at $3.67 on Friday. The company has a quick ratio of 4.60, a current ratio of 4.60 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1.91 billion, a P/E ratio of -2.48 and a beta of 0.95. The business has a fifty day moving average of $4.18 and a two-hundred day moving average of $4.70. Recursion Pharmaceuticals has a twelve month low of $2.98 and a twelve month high of $7.89.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.07. The firm had revenue of $35.54 million during the quarter, compared to analyst estimates of $24.56 million. Recursion Pharmaceuticals had a negative return on equity of 66.70% and a negative net margin of 863.37%.The business’s revenue for the quarter was up 671.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.53) EPS. On average, analysts forecast that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In other news, CFO Ben R. Taylor sold 21,383 shares of the stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $4.18, for a total value of $89,380.94. Following the transaction, the chief financial officer directly owned 761,550 shares of the company’s stock, valued at approximately $3,183,279. This represents a 2.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Najat Khan sold 124,403 shares of the firm’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $4.41, for a total value of $548,617.23. Following the completion of the transaction, the insider owned 611,135 shares of the company’s stock, valued at approximately $2,695,105.35. The trade was a 16.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 819,212 shares of company stock valued at $3,523,950 in the last ninety days. Company insiders own 8.43% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Invesco Ltd. lifted its stake in Recursion Pharmaceuticals by 25.8% during the 4th quarter. Invesco Ltd. now owns 526,144 shares of the company’s stock valued at $2,152,000 after acquiring an additional 107,979 shares during the period. Corient Private Wealth LLC acquired a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth $70,000. Mercer Global Advisors Inc. ADV raised its holdings in shares of Recursion Pharmaceuticals by 55.5% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 25,020 shares of the company’s stock worth $100,000 after purchasing an additional 8,935 shares during the last quarter. NewEdge Advisors LLC lifted its position in Recursion Pharmaceuticals by 149.5% during the fourth quarter. NewEdge Advisors LLC now owns 33,757 shares of the company’s stock valued at $138,000 after purchasing an additional 20,226 shares during the period. Finally, XTX Topco Ltd lifted its position in Recursion Pharmaceuticals by 104.0% during the fourth quarter. XTX Topco Ltd now owns 47,908 shares of the company’s stock valued at $196,000 after purchasing an additional 24,421 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

Key Stories Impacting Recursion Pharmaceuticals

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: Q4 beat on EPS and revenue — Recursion reported narrower-than-expected Q4 loss (EPS -$0.21 vs. -$0.28 est.) and materially beat revenue estimates, driven partly by partner milestones. The results and upbeat metrics were the primary catalyst lifting the stock after the print. RXRX Q4 Loss Narrower Than Expected
• Positive Sentiment: Revenue jump / partner milestone extends runway — FY2025 revenue rose materially (reported ~$74.7M), with Roche-related milestone revenue cited as extending Recursion’s cash runway into 2028, reducing near-term financing risk. Recursion Q4 2025 Earnings Call Highlights
• Positive Sentiment: Clinical progress — Management highlighted advancement of programs (e.g., REC-4881 entering clinical stages), signalling the company is moving from discovery to clinical validation — a tangible de‑risking step for an AI-driven biotech. Recursion Hits Clinical Milestones
• Positive Sentiment: Analyst support — Needham reaffirmed a “buy” and set an $8 price target, giving investors a visible upside case and supporting momentum after the print. Needham Rating
• Neutral Sentiment: Earnings call emphasized strategy and partnerships — Management framed 2025 as a transition year (scale data + ML + clinical starts); useful for long-term thesis but not an immediate earnings driver. Earnings Call Summary
• Neutral Sentiment: Disclosure/analysis availability — Full call transcript and presentation were posted (useful for modelers and event traders). Earnings Presentation
• Negative Sentiment: Still unprofitable and wide negative margins — Despite the beat, Recursion remains loss-making (negative net margin/ROE) and analysts forecast negative FY EPS, leaving valuation and path to sustained profitability as open questions. AAII Analysis
• Negative Sentiment: Technical / liquidity headwinds — The stock traded below key moving averages with volume below its recent average, and remains volatile; those factors can pressure price even after positive news. Market Reaction

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.